<SEC-DOCUMENT>0000895345-25-000072.txt : 20250214
<SEC-HEADER>0000895345-25-000072.hdr.sgml : 20250214
<ACCEPTANCE-DATETIME>20250214170044
ACCESSION NUMBER:		0000895345-25-000072
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250214
DATE AS OF CHANGE:		20250214

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akebia Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001517022
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				208756903
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-88058
		FILM NUMBER:		25630550

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-871-2098

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Satter Muneer A
		CENTRAL INDEX KEY:			0001315797
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	MAIL ADDRESS:	
		STREET 1:		C/O SATTER INVESTMENT MANAGEMENT, LLC
		STREET 2:		676 NORTH MICHIGAN AVENUE, SUITE 4000
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60611
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0000895345-22-000827</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001315797</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>3</amendmentNo>
<securitiesClassTitle>Common Stock, par value $0.00001</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/31/2024</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001517022</issuerCik>
<issuerName>Akebia Therapeutics, Inc.</issuerName>
<issuerCusip>00972D105</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>245 FIRST STREET</com:street1>
<com:city>CAMBRIDGE</com:city>
<com:stateOrCountry>MA</com:stateOrCountry>
<com:zipCode>02142</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Satter Muneer A</reportingPersonName>
<citizenshipOrOrganization>X1</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>5747906</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>5747906</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>5747906</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>2.6</classPercent>
<typeOfReportingPerson>IN</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Akebia Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>245 FIRST STREET, CAMBRIDGE, Massachusetts, 02142</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>Muneer A. Satter</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>Muneer A. Satter&#13;
c/o Alerce Investment Management, L.P.&#13;
676 North Michigan Avenue, Suite 4000&#13;
Chicago, IL 60611</principalBusinessOfficeOrResidenceAddress>
<citizenship>United States of America</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>5,747,906&#13;
The shares of Common Stock beneficially owned by the Reporting Person include (a) 4,097,657 shares that are held by Alerce Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares; (b) 939,947 shares that are held by Satter Medical Technology Partners, L.P. for which the Reporting Person has sole voting and dispositive power over all such shares; (c) 278,558 shares of Common Stock that are held by Muneer A. Satter Revocable Trust for which the Reporting Person serves as trustee and, in such capacity, has sole voting and dispositive power over all such shares; and (d) 431,744 shares of Common Stock that are held by various other trusts and other entities for which the Reporting Person serves as trustee, investment advisor or manager and, in such capacity, has sole voting and dispositive power over all such shares.</amountBeneficiallyOwned>
<classPercent>2.6</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>5,747,906</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>5,747,906</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>N</notApplicableFlag>
<classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Satter Muneer A</reportingPersonName>
<signatureDetails>
<signature>/s/ Muneer A. Satter</signature>
<title>Satter Muneer A</title>
<date>02/07/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
